# Syner-G BioPharma Group

> Syner-G BioPharma Group (formerly Sequoia Biotech Consulting) is a strategic development and delivery partner to biopharma innovators. The company helps biotech and pharmaceutical organizations navigate scientific, regulatory, operational, and strategic challenges to accelerate drug development from discovery to commercialization. Syner-G brings integrated expertise across CMC, regulatory affairs, quality, medical writing, clinical supply, and business transformation, embedding expert teams alongside clients to drive results.

Key details:

- Website: https://synergbiopharma.com
- Tagline: "From science to success.™"
- Global presence with operations serving clients across the US and internationally
- High client return rate; 500+ subject matter experts; 1,000+ client engagements; 1,000+ assets supported
- LinkedIn: https://www.linkedin.com/company/syner-g-pharma-cmc-consulting-llc/

## Solutions Overview

- [Strategic Development & Delivery Partner](https://synergbiopharma.com/solutions/strategic-development-delivery-partner/): Integrated science, strategy, and delivery to accelerate development and reduce risk.
- [Scientific, Regulatory & Quality](https://synergbiopharma.com/solutions/scientific-regulatory-quality-solutions/): De-risk and accelerate the path to approval with deep CMC, regulatory, and quality expertise.
- [Strategy & Transformation Consulting](https://synergbiopharma.com/solutions/strategy-transformation-consulting/): M&A integration, digital and AI transformation, and organizational design for life sciences.
- [Technical Operations & Delivery Infrastructure](https://synergbiopharma.com/solutions/technical-operations-delivery-infrastructure-solutions/): Embedded operational leadership to scale execution and drive GMP performance.
- [Digital & AI Transformation](https://synergbiopharma.com/solutions/digital-ai-transformation/): AI and digital strategy for biopharma operations and development.

## Solutions by Company Stage

- [Emerging & Early-Stage Biotech](https://synergbiopharma.com/solutions/emerging-early-stage-biotech/)
- [Mid-Sized to Large Enterprise Biopharma](https://synergbiopharma.com/solutions/mid-to-large-enterprise-biopharma/)
- [Private Equity & Investors](https://synergbiopharma.com/solutions/private-equity-investors/)

## Solutions by Development Stage

- [Discovery](https://synergbiopharma.com/solutions/discovery-stage/)
- [Preclinical](https://synergbiopharma.com/solutions/preclinical-stage/)
- [Clinical](https://synergbiopharma.com/solutions/clinical-stage/)
- [Commercialization](https://synergbiopharma.com/solutions/commercialization-stage/)

## Solutions by Product Modality

- [Biologics](https://synergbiopharma.com/solutions/biologics/)
- [Small Molecule](https://synergbiopharma.com/solutions/small-molucule/)
- [Cell & Gene Therapy](https://synergbiopharma.com/solutions/cell-gene-therapy/)
- [Diagnostics & Medical Device](https://synergbiopharma.com/solutions/diagnostics-medical-device/)

## Scientific, Regulatory & Quality Solutions

- [CMC Consulting](https://synergbiopharma.com/solutions/cmc-consulting/)
- [CMC Strategy & Development](https://synergbiopharma.com/solutions/cmc-strategy-development/)
- [CMC Project Management](https://synergbiopharma.com/solutions/cmc-project-management/)
- [Pharmaceutical Development (CMC)](https://synergbiopharma.com/solutions/pharmaceutical-development-cmc/)
- [Regulatory CMC](https://synergbiopharma.com/solutions/regulatory-cmc/)
- [CMC Technical Writing & Electronic Publishing](https://synergbiopharma.com/solutions/cmc-technical-writing-electronic-publishing/)
- [IND/CTA and BLA/NDA Strategy, Submissions & Management](https://synergbiopharma.com/solutions/ind-cta-and-bla-nda-strategy-submissions-management-services/)
- [Regulatory Strategy](https://synergbiopharma.com/solutions/regulatory-strategy/)
- [Regulatory Consulting – End-to-End Strategy](https://synergbiopharma.com/solutions/regulatory-consulting-end-to-end-strategy/)
- [Non-Clinical & Clinical Strategy](https://synergbiopharma.com/solutions/non-clinical-clinical-strategy/)
- [Medical Writing](https://synergbiopharma.com/solutions/medical-writing/)
- [Scientific & Technical Writing](https://synergbiopharma.com/solutions/scientific-technical-writing/)
- [Quality & Compliance](https://synergbiopharma.com/solutions/quality-compliance/)
- [QC Services](https://synergbiopharma.com/solutions/qc-services/)
- [Clinical Supply Management](https://synergbiopharma.com/solutions/clinical-supply-management/)
- [Discovery Sciences](https://synergbiopharma.com/solutions/discovery-sciences/)
- [Functional Outsourcing Partnerships](https://synergbiopharma.com/solutions/functional-outsourcing-partnerships/)

## Strategy & Transformation Consulting Solutions

- [Business Transformation](https://synergbiopharma.com/solutions/business-transformation/)
- [Business Excellence](https://synergbiopharma.com/solutions/business-excellence/)
- [Mergers & Acquisitions Integration](https://synergbiopharma.com/solutions/mergers-acquisitions-integration/)
- [Program & Portfolio Management](https://synergbiopharma.com/solutions/program-portfolio-management/)
- [Organizational Change](https://synergbiopharma.com/solutions/organizational-change/)
- [Workforce Transformation](https://synergbiopharma.com/solutions/workforce-transformation/)

## Technical Operations & Delivery Infrastructure Solutions

- [Biomanufacturing](https://synergbiopharma.com/solutions/biomanufacturing/)
- [GMP Operations & Engineering](https://synergbiopharma.com/solutions/gmp-operations-engineering/)
- [GMP Infrastructure & Systems](https://synergbiopharma.com/solutions/gmp-infrastructure-systems/)
- [Technical Facilities Management](https://synergbiopharma.com/solutions/technical-facilities-management/)

## About

- [Why Syner-G](https://synergbiopharma.com/why-syner-g/)
- [Global Presence](https://synergbiopharma.com/global-presence/)
- [News & Media](https://synergbiopharma.com/news-media/)
- [Press Releases](https://synergbiopharma.com/press-releases/)
- [Media Hits](https://synergbiopharma.com/media-hits/)
- [In the Media](https://synergbiopharma.com/in-the-media/)
- [Sequoia Biotech Consulting → Syner-G Rebrand](https://synergbiopharma.com/sequoia-biotech-consulting-now-syner-g/)

## Our People

- [Executive Leadership](https://synergbiopharma.com/executive-leadership/)
- [Practice Leaders](https://synergbiopharma.com/practice-leaders/)
- [Board of Directors](https://synergbiopharma.com/board-of-directors/)
- [Advisory Board](https://synergbiopharma.com/advisory-board/)

## Careers

- [Careers & Culture](https://synergbiopharma.com/careers/)
- [India Careers](https://synergbiopharma.com/india-careers/)

## Resources

- [All Resources](https://synergbiopharma.com/resources/)
- [Blog](https://synergbiopharma.com/blog/)
- [Case Studies](https://synergbiopharma.com/case-studies/)
- [White Papers](https://synergbiopharma.com/white-papers/)
- [Webinars](https://synergbiopharma.com/webinars/)
- [Infographics](https://synergbiopharma.com/infographics/)
- [Posters](https://synergbiopharma.com/posters/)
- [Playbooks](https://synergbiopharma.com/playbooks/)
- [Bio Books](https://synergbiopharma.com/bio-books/)
- [Article Archive](https://synergbiopharma.com/article-archive/)
- [Upcoming Events](https://synergbiopharma.com/upcoming-events/)
- [Newsletter Sign-Up](https://synergbiopharma.com/newsletter-sign-up/)
- [Contact Us](https://synergbiopharma.com/contact-us/)

## Case Studies

- [Zero Questions: A Phase 2 IND, Two Tech Transfers, and a 10-Person Biotech](https://synergbiopharma.com/case-study/zero-questions-a-phase-2-ind-two-tech-transfers-and-a-10-person-biotech/)
- [From CRL to Approval: End-to-End BLA Lifecycle Support for a Phase 3 Biologic Program](https://synergbiopharma.com/case-study/from-crl-to-approval-end-to-end-bla-lifecycle-support-for-a-phase-3-biologic-program/)
- [From Licensing to Acquisition: End-to-End CMC Enablement for a Clinical-Stage Biotech](https://synergbiopharma.com/case-study/from-licensing-to-acquisition-end-to-end-cmc-enablement-for-a-clinical-stage-biotech/)
- [The Journey Leading to an Approved NDA](https://synergbiopharma.com/case-study/the-journey-leading-to-an-approved-nda/)
- [The Critical Role of CQV Leadership in Achieving GMP-Ready Cell & Gene Therapy Production](https://synergbiopharma.com/case-study/the-critical-role-of-cqv-leadership-in-achieving-gmp-ready-cell-gene-therapy-production/)
- [Driving Operational Excellence: Optimizing a QMS for a State-of-the-Art Biomanufacturing Facility](https://synergbiopharma.com/case-study/driving-operational-excellence-optimizing-a-quality-management-system-for-a-state-of-the-art-biomanufacturing-facility/)
- [From Data to Dossier: Smart Scale-Up Solutions in Biopharmaceutical Manufacturing](https://synergbiopharma.com/case-study/from-data-to-dossier-smart-scale-up-solutions-in-biopharmaceutical-manufacturing/)
- [From CDMO to In-House cGMP Manufacturing: Cell Therapy Technology Transfer](https://synergbiopharma.com/case-study/from-cdmo-to-in-house-cgmp-manufacturing-scaling-success-in-cell-therapy-technology-transfer/)
- [Revolutionizing Supply Chains: A Roadmap to Automation and Agility](https://synergbiopharma.com/case-study/revolutionizing-supply-chains-a-roadmap-to-automation-and-agility/)
- [Syner-G Partners with Leading Supplier to Build New cGMP-Compliant Facilities](https://synergbiopharma.com/case-study/syner-g-partners-with-leading-supplier-in-life-sciences-to-build-out-new-cgmp-compliant-facilities/)
- [Driving Long-Term Value Through a People-Centered M&A Integration](https://synergbiopharma.com/case-study/driving-long-term-value-through-a-people-centered-execution-focused-approach-to-ma-integration/)
- [Regulatory Operations Department Developed and Flourishing](https://synergbiopharma.com/case-study/regulatory-operations-department-developed-and-flourishing/)
- [Global Biotechnology Company Partners to Implement a Successful Change Initiative](https://synergbiopharma.com/case-study/global-biotechnology-company-partners-to-implement-a-successful-change-initiative/)
- [Successful Partnership Improved Efficiencies and Reduced Overall Spend](https://synergbiopharma.com/case-study/successful-partnership-improved-efficiencies-and-reduced-overall-spend/)
- [U.S. Independent Biotech Finds Success in Syner-G's Manufacturing Capabilities](https://synergbiopharma.com/case-study/u-s-based-independent-biotech-company-finds-success-in-syner-gs-capabilities-in-manufacturing-for-both-pre-clinical-and-clinical-trials-case-studies/)
- [Process Improvements Help U.S. Pharma Achieve On-Time Phase III Clinical Trials](https://synergbiopharma.com/case-study/process-improvements-and-in-person-monitoring-help-u-s-pharmaceutical-company-achieve-on-time-for-phase-iii-clinical-trials/)
- [U.S. Pharma Improved Quality of Documentation, Saving Time and Filing Delays](https://synergbiopharma.com/case-study/u-s-pharmaceutical-company-improved-quality-of-overall-documentation-saving-time-and-filing-delays/)
- [Expert Regulatory Affairs Services for a European-Based Client](https://synergbiopharma.com/case-study/expert-regulatory-affairs-services-for-a-european-based-client/)
- [Successful US & EU Marketing Applications for Big Pharma](https://synergbiopharma.com/case-study/successful-us-eu-marketing-applications-for-big-pharma/)
- [Virtual U.S. Biopharma Company Sees Improvement in Quality Culture and Drug Supply Compliance](https://synergbiopharma.com/case-study/virtual-u-s-biopharma-company-sees-overall-improvement-in-quality-culture-and-ensured-uninterrupted-supply-of-compliant-ds/)
- [Syner-G's Strategic Leadership in Regulatory Conformance Checks](https://synergbiopharma.com/case-study/syner-g-biopharmas-strategic-leadership-in-regulatory-conformance-checks/)
- [Syner-G Helps Biotech Firm Advance Life-Saving Drug Through Manufacturing Startup and Clinical Trials](https://synergbiopharma.com/case-study/syner-g-helps-biotech-firm-successfully-advance-life-saving-drug-through-manufacturing-startup-and-clinical-trials/)
- [Strategic CMC Development Partnership Enabling Timely Approval and Launch of a Breakthrough Product](https://synergbiopharma.com/case-study/strategic-cmc-development-partnership-enabling-timely-approval-and-launch-of-a-breakthrough-product/)
- [Partnership with Canadian Pharma Resulted in Savings for a Time-Critical Clinical Program](https://synergbiopharma.com/case-study/partnership-with-a-canadian-pharma-organization-resulted-in-savings-in-effort-and-material-cost-for-time-critical-clinical-program/)
- [Synthesizing Success: Strategic Solutions for Elevating a Biotech Innovator](https://synergbiopharma.com/case-study/synthesizing-success-syner-gs-strategic-solutions-for-elevating-a-biotech-innovator/)
- [Advancing Biotech Drug Development: Collaborative Approach to CMC](https://synergbiopharma.com/case-study/advancing-biotech-drug-development-syner-g-biopharmas-collaborative-approach-to-chemistry-manufacturing-and-controls/)
- [From Collaboration to Compliance: A Strategic Initiative for a Safer Workplace](https://synergbiopharma.com/case-study/from-collaboration-to-compliance-a-strategic-initiative-for-a-safer-workplace/)
- [Mobilizing Pharmaceutical Technology Transfers to a CDMO](https://synergbiopharma.com/case-study/mobilizing-pharmaceutical-technology-transfers-to-a-contract-development-and-manufacturing-organization-cdmo/)
- [Establishment of a Long-Term Medical Writing Partnership](https://synergbiopharma.com/case-study/establishment-of-a-long-term-medical-writing-partnership/)
- [Regulatory Affairs Strategy and Project Team Lead](https://synergbiopharma.com/case-study/regulatory-affairs-strategy-and-project-team-lead/)
- [Partnership Helped Reduce Time to Market for U.S. Virtual Biopharmaceutical Company](https://synergbiopharma.com/case-study/partnership-helped-to-reduce-time-to-market-by-ensuring-for-u-s-based-virtual-biopharmaceutical-company/)
- [Regulatory Expectations for Sterile Filtration Process Control](https://synergbiopharma.com/case-study/regulatory-expectations-for-sterile-filtration-process-control/)

## Blog

- [Regulatory Affairs in Gene Therapy](https://synergbiopharma.com/blog/regulatory-affairs-gene-therapy/)
- [Pharmacokinetics vs. Pharmacodynamics](https://synergbiopharma.com/blog/pharmacokinetics-vs-pharmacodynamics/)
- [Human Factors in Medical Devices](https://synergbiopharma.com/blog/human-factors-medical-devices/)
- [IND vs. NDA](https://synergbiopharma.com/blog/ind-vs-nda/)
- [Clinical Study Report](https://synergbiopharma.com/blog/clinical-study-report/)
- [What Is an IND?](https://synergbiopharma.com/blog/what-is-ind/)
- [Preparing Professionals for a Regulatory Medical Writing Career](https://synergbiopharma.com/blog/preparing-professionals-for-regulatory-medical-writing-career/)
- [Why Are Biologics Drugs Different?](https://synergbiopharma.com/blog/why-are-biologics-drugs-different/)
- [7 Strategic Benefits of Using AI in Biopharma](https://synergbiopharma.com/blog/benefits-of-using-ai-in-biopharma/)
- [Another Nitrosamine Recall — Another Reminder This Problem Isn't Going Away](https://synergbiopharma.com/blog/another-nitrosamine-recall-another-reminder-that-this-problem-isnt-going-away/)
- [Biopharma Strategy Consulting: A Complete Guide](https://synergbiopharma.com/blog/biopharma-strategy-consulting-a-complete-guide/)
- [Post-Approval CMC Changes](https://synergbiopharma.com/blog/post-approval-cmc-changes/)
- [Early Regulatory Strategy for Biotech Startups](https://synergbiopharma.com/blog/early-regulatory-strategy-biotech-startups/)
- [Quality Gaps and Drug Development Delays](https://synergbiopharma.com/blog/quality-gaps-drug-development-delays/)
- [Using Non-Animal Toxicology: Start with the FDA Conversation](https://synergbiopharma.com/blog/using-non-animal-toxicology-start-with-the-fda-conversation/)
- [When to Outsource Regulatory, Quality & CMC Support](https://synergbiopharma.com/blog/when-to-outsource-regulatory-quality-cmc-support/)
- [Why Most Drug Development Programs Stall Before Approval](https://synergbiopharma.com/blog/why-most-drug-development-programs-stall-before-approval-and-how-to-prevent-it/)
- [Biopharma Commercial Readiness Guide](https://synergbiopharma.com/blog/biopharma-commercial-readiness-guide/)
- [CRO vs. CMO vs. CDMO](https://synergbiopharma.com/blog/cro-cmo-cdmo/)
- [Digital Transformation in Pharma](https://synergbiopharma.com/blog/digital-transformation-pharma/)
- [Biopharma M&A Trends](https://synergbiopharma.com/blog/biopharma-ma-trends/)
- [Pharma Data Integrity](https://synergbiopharma.com/blog/pharma-data-integrity/)
- [Digital QMS for Pharma](https://synergbiopharma.com/blog/digital-qms-pharma/)
- [Clinical Trial Supply Chain Risk](https://synergbiopharma.com/blog/clinical-trial-supply-chain-risk/)
- [Breakthrough Therapy Designations](https://synergbiopharma.com/blog/breakthrough-therapy-designations/)
- [FDA PreCheck Pilot](https://synergbiopharma.com/blog/fda-precheck-pilot-a-smarter-infrastructure-centered-alternative-to-fast-track-and-breakthrough-designations/)
- [Why FDA PreCheck Is a Game-Changer for Small & Mid-Sized Pharma](https://synergbiopharma.com/blog/why-fda-precheck-is-a-game-changer-for-small-mid-sized-pharma-and-how-these-companies-should-lean-in/)
- [From Fast Track to PreCheck: A New Era in FDA Readiness Programs](https://synergbiopharma.com/blog/from-fast-track-to-precheck-a-new-era-in-fda-readiness-programs/)
- [The US-China Trade War and Investigational Drug Supply Chains](https://synergbiopharma.com/blog/the-us-china-trade-war-and-its-impacts-on-investigational-drug-supply-chains/)
- [The Real Cost of Uncertainty: On-Again Off-Again Tariffs and Biotech Supply Chains](https://synergbiopharma.com/blog/the-real-cost-of-uncertainty-why-on-again-off-again-tariffs-hurt-biotech-supply-chains/)
- [Manufacturing Gaps in the U.S. Pharmaceutical Industry Exposed by Tariff Wars](https://synergbiopharma.com/blog/manufacturing-gaps-in-the-u-s-pharmaceutical-industry-exposed-by-tariff-wars/)
- [Building a QMS for Medical Devices](https://synergbiopharma.com/blog/building-a-qms-quality-management-system-for-medical-device/)
- [CMC Manufacturing](https://synergbiopharma.com/blog/cmc-manufacturing/)
- [What Is GMP Audit?](https://synergbiopharma.com/blog/what-is-gmp-audit/)
- [GMP Stability Storage](https://synergbiopharma.com/blog/gmp-stability-storage/)
- [Key Takeaways from JPM 2026](https://synergbiopharma.com/blog/key-takeaways-from-jpm-2026-what-we-heard-what-it-means/)
- [What Is Process Control?](https://synergbiopharma.com/blog/what-is-process-control/)
- [Understanding Large Molecules in Drug Discovery](https://synergbiopharma.com/blog/understanding-large-molecules-in-drug-discovery/)
- [FDA Approval Process for Medications](https://synergbiopharma.com/blog/fda-approval-process-for-medications/)
- [FDA Approval Process for Medical Devices](https://synergbiopharma.com/blog/fda-approval-process-for-medical-devices/)
- [FDA Approval Process for Vaccines](https://synergbiopharma.com/blog/fda-approval-process-for-vaccines/)
- [BLA vs. NDA](https://synergbiopharma.com/blog/bla-vs-nda/)
- [NDA vs. ANDA](https://synergbiopharma.com/blog/nda-vs-anda/)
- [Regulatory Strategy in Drug Development](https://synergbiopharma.com/blog/regulatory-strategy-drug-development/)
- [Regulatory Affairs Project Manager](https://synergbiopharma.com/blog/regulatory-affairs-project-manager/)
- [Regulatory Affairs in Pharma: Roles and Compliance Strategies](https://synergbiopharma.com/blog/regulatory-affairs-compliance-strategies/)
- [Role of Regulatory Affairs in the Pharmaceutical Industry](https://synergbiopharma.com/blog/role-regulatory-affairs-in-pharmaceutical-industry/)
- [Regulatory Medical Writing: What Is It and What Do They Do?](https://synergbiopharma.com/blog/regulatory-medical-writing-what-is-it-and-what-do-they-do/)
- [Medical Writing vs. Regulatory Affairs](https://synergbiopharma.com/blog/medical-writing-vs-regulatory-affairs/)
- [What Is Pharmacodynamics?](https://synergbiopharma.com/blog/what-is-pharmacodynamics/)
- [What Is Fast Track Designation?](https://synergbiopharma.com/blog/what-is-fast-track-designation/)
- [Pharma Product Lifecycle](https://synergbiopharma.com/blog/pharma-product-lifecycle/)
- [Understanding FDA's Evolving Expectations for Biopharma Compliance](https://synergbiopharma.com/blog/understanding-the-fdas-evolving-expectations-for-biopharma-compliance/)
- [Breakthrough Therapies Drug Development Guide](https://synergbiopharma.com/blog/breakthrough-therapies-drug-development-guide/)
- [CMC Safety & Efficacy in Gene & Cell Therapies](https://synergbiopharma.com/blog/cmc-safety-efficacy-in-gene-cell-therapies/)
- [Regulatory Pathway for Medical Devices](https://synergbiopharma.com/blog/regulatory-pathway-medical-devices/)
- [Accelerating Drug Development with Breakthrough Therapy Designations](https://synergbiopharma.com/blog/accelerating-drug-development-breakthrough-therapy-designations/)
- [From Milligrams to IND Supply: Entering Early CMC with Confidence](https://synergbiopharma.com/blog/from-milligrams-to-ind-supply-entering-early-cmc-with-confidence/)
- [The Hidden Bottleneck in Drug Discovery: Medicinal Chemistry Resource Gaps](https://synergbiopharma.com/blog/the-hidden-bottleneck-in-drug-discovery-medicinal-chemistry-resource-gaps/)
- [From Science to Success: Why CQV Is the Missing Link in Advanced Therapy Operational Readiness](https://synergbiopharma.com/blog/from-science-to-success-why-cqv-is-the-missing-link-in-advanced-therapy-operational-readiness/)
- [Why Human Oversight Is the Secret Ingredient in Supply Chain Automation](https://synergbiopharma.com/blog/why-human-oversight-is-the-secret-ingredient-in-supply-chain-automation/)
- [Managing Complexity: How Strategic Execution Drove a Cleanroom Upgrade to Completion](https://synergbiopharma.com/blog/managing-complexity-how-strategic-execution-drove-a-cleanroom-upgrade-project-to-completion/)
- [Building the Future of Breakthrough Therapies Together](https://synergbiopharma.com/blog/building-the-future-of-breakthrough-therapies-together/)
- [291 FDA Complete Response Letters Decoded](https://synergbiopharma.com/blog/291-fda-complete-response-letters-decoded-insights-for-biologics-cmc-strategy/)
- [Oral Drug Product Development of Small Molecules](https://synergbiopharma.com/blog/oral-drug-product-development-of-small-molecules/)
- [Why Strong Technical-Regulatory Alignment Matters](https://synergbiopharma.com/blog/why-strong-technical-regulatory-alignment-matters/)
- [The Startup's Guide: 10 Must-Have CMC SOPs for Virtual Pharma in Phase 1](https://synergbiopharma.com/blog/the-startups-guide-10-must-have-cmc-sops-for-virtual-pharma-in-phase-1/)
- [Quality Tools & Resources for QC Specialists in Medical Writing](https://synergbiopharma.com/blog/quality-tools-resources-for-quality-control-specialists-in-medical-writing/)
- [Accelerating a Cytotoxic Peptide Drug Conjugate to IND](https://synergbiopharma.com/blog/accelerating-a-cytotoxic-peptide-drug-conjugate-to-ind-a-medicinal-chemists-journey-to-ind-with-syner-g-biopharma-group/)
- [Women's History Month 2025](https://synergbiopharma.com/blog/womens-history-month-2025/)

## Optional

- [Privacy Policy](https://synergbiopharma.com/privacy-policy/)
- [Cookie Policy](https://synergbiopharma.com/cookie-policy/)
- [Terms of Service](https://synergbiopharma.com/terms-of-service/)
- [Data Privacy Framework Policy](https://synergbiopharma.com/data-privacy-framework-policy/)

- [North American Careers](https://synergbiopharma.com/north-american-careers/)
- [Common CDMO Contract Pitfalls (and How to Avoid Them)](https://synergbiopharma.com/blog/cdmo-contract-pitfalls/): A biopharma CDMO contract is a vital risk-control mechanism across CMC, quality, and regulatory operations, not a mere procurement formality. Standard agreements frequently appear complete until a failed batch, delayed clinical supply, or stalled data transfer exposes unassigned liability. Drawing on our integrated CMC, quality, regulatory, and external-manufacturing oversight, here are eight practical contracting checks […]
- [When to Outsource Manufacturing to a CDMO vs. Build In-House](https://synergbiopharma.com/blog/cdmo-vs-in-house-manufacturing/): Are you buying speed and flexibility, or are you building control and long-term capacity? For biopharma executives, deciding when to outsource manufacturing to a CDMO vs. build in-house is never a simple philosophical preference. It is a high-stakes capital allocation and risk decision where a wrong call can cost years of program delay, tens of […]
- [Managing a CDMO Relationship: Oversight & Governance](https://synergbiopharma.com/blog/cdmo-oversight-governance-best-practices/): Outsourcing manufacturing does not outsource accountability. When a batch fails, a deviation delays release, or a regulator questions process control, the sponsor remains responsible for product quality, supply continuity, and the decisions that support them. Managing a CDMO relationship requires active oversight and governance, not vendor administration. This lifecycle-long discipline connects technical operations, quality assurance, […]
- [CDMO Selection Criteria for Biologics & Advanced Therapies](https://synergbiopharma.com/blog/cdmo-selection-biologics/): Applying generic vendor checklists to drug development creates operational risk. Traditional biologics and cell or gene therapies demand vastly different risk profiles, analytical assays, and cold-chain logistics. This framework outlines the core CDMO selection criteria for biologics and advanced therapies, covering nine areas to ask and verify. Built for biopharma leaders evaluating partners across monoclonal […]